Sampatrilat

Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP) . Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM) . Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation[1][2].

Product Specifications

CAS Number

[129981-36-8]

Product Name Alternative

UK-81252

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Angiotensin-converting Enzyme (ACE) ; Neprilysin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/sampatrilat.html

Purity

99.22

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC([C@H](CNC([C@@H](NS(C)(=O)=O)CCCCN)=O)CC1(CCCC1)C(N[C@H](C(O)=O)CC2=CC=C(O)C=C2)=O)=O

Molecular Formula

C26H40N4O9S

Molecular Weight

584.68

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Sharma RK, et al. The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme. J Chem Inf Model. 2016 Dec 27;56 (12) :2486-2494.|[2]Maki T, et al. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.J Pharmacol Exp Ther. 2003 Apr;305 (1) :97-105.